MeT5A-BAP1w-/KO have stably reduced BAP1 expression and, given that BAP1 mutation is an early truncal change (8), represent a more relevant model to study tumor biology and drug sensitivity than modulation of BAP1 in established cancer cell lines that already harbor a spectrum of tumorigenic mutations. The gene discussed is BAP1; the disease is cancer.